Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12965
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFrauman, Albert Gen
dc.contributor.authorCooper, Mark Een
dc.contributor.authorParsons, B Jen
dc.contributor.authorJerums, Georgeen
dc.contributor.authorLouis, William Jen
dc.date.accessioned2015-05-16T02:43:56Z
dc.date.available2015-05-16T02:43:56Z
dc.date.issued1987-09-10en
dc.identifier.citationDiabetes Care; 10(5): 573-8en
dc.identifier.govdoc3315514en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/12965en
dc.description.abstractThis study, in 3 phases, compared the long-term acceptability and efficacy of insulin administered by nasal spray with an intensified subcutaneous regimen in nine type I (insulin-dependent) diabetic subjects on baseline therapy with ultralente insulin. In phase 1, patients were begun and stabilized on a regimen of ultralente daily and Actrapid insulin three times daily. Phase 2 consisted of 4 mo of this intensified subcutaneous regimen. In phase 3, intranasal administration of insulin, with 1% (wt/vol) sodium glycocholate, replaced Actrapid insulin for 4 mo. Glycemic control was compared in each of the three phases. It was possible to maintain the dose of ultralente insulin relatively constant in only six of the nine subjects during the intranasal phase of the study. The six subjects showed a significant rise in glycosylated hemoglobin during the intranasal phase (10.4 +/- 0.6% intranasal vs. 9.1 +/- 0.3% subcutaneous, P less than .05) but not in plasma or urinary glucose levels. There was no significant change in the incidence of hypoglycemic episodes during intranasal insulin therapy in this group. The other three subjects were considered treatment failures. Six of the nine original subjects expressed a preference for intranasal insulin, and one subject complained of mild nasal irritation insufficient to cease treatment. The intranasal route of administration of insulin has the potential to replace short-acting insulin as an adjunct to longer-acting insulin in some insulin-treated diabetic patients.en
dc.language.isoenen
dc.subject.otherAdministration, Intranasalen
dc.subject.otherAdolescenten
dc.subject.otherAdulten
dc.subject.otherAerosolsen
dc.subject.otherDiabetes Mellitus, Type 1.drug therapyen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherInjections, Subcutaneousen
dc.subject.otherInsulin.administration & dosage.therapeutic useen
dc.subject.otherInsulin, Isophane.administration & dosage.therapeutic useen
dc.subject.otherInsulin, Long-Acting.administration & dosage.therapeutic useen
dc.subject.otherInsulin, Regular, Porken
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherTime Factorsen
dc.titleLong-term use of intranasal insulin in insulin-dependent diabetic patients.en
dc.typeJournal Articleen
dc.identifier.journaltitleDiabetes Careen
dc.identifier.affiliationDepartment of Clinical Pharmacology, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.description.pages573-8en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/3315514en
dc.type.austinJournal Articleen
local.name.researcherFrauman, Albert G
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptClinical Pharmacology and Therapeutics-
crisitem.author.deptEndocrinology-
crisitem.author.deptClinical Pharmacology and Therapeutics-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

14
checked on Mar 29, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.